Phase II study of sunitinib in patients with metastatic urothelial cancer. - Wikidata - awgldk - TriplyDB

Phase II study of sunitinib in patients with metastatic urothelial cancer.

Phase II study of sunitinib in patients with metastatic urothelial cancer.

http://www.wikidata.org/entity/Q43168171

about

Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer Targeted therapy in advanced bladder cancer: what have we learned?Role of systemic chemotherapy in urothelial urinary bladder cancer Multimodal management of muscle-invasive bladder cancer Targeting Hsp90 in urothelial carcinoma Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.Systemic therapy in bladder cancer Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials.Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.Chemotherapy in advanced bladder cancer: current status and future Personalized therapy for urothelial cancer: review of the clinical evidence.Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma Novel strategies for treating relapsed/refractory urothelial carcinoma.Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma New therapeutic targets in the management of urothelial carcinoma of the bladder Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines.Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin - preliminary results.Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.Vinflunine in the treatment of advanced bladder cancer.Current chemotherapeutic strategies against bladder cancer.Management of advanced bladder cancer in patients with impaired renal function.Current treatment of metastatic bladder cancer and future directions.Urothelial cancers: using biology to improve outcomes.Novel molecular targets for the therapy of urothelial carcinoma.Novel immunotherapies in GU malignancies.Molecular targets on the horizon for kidney and urothelial cancer.Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.Sunitinib malate in the treatment of urothelial cancer.Emerging drugs for urothelial carcinoma.Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review.

P2860

Q26744758-ABEBF172-40D6-43FF-8231-FEF1D070966D Q27009469-5C51D968-0818-4114-A094-1B20EECD48AB Q27010323-55463E47-686B-45A9-9672-F26FAB6A9077 Q27011624-A51F8685-47A2-434B-A1EB-B8EE948CF74C Q27023406-AF409A52-C4EB-4EBA-AA8F-2E7953D2B93F Q28084715-10E981B9-B6D5-418C-A7DD-A87CD794BE6A Q29012696-25BC9551-5E0D-4F97-9BC3-0E0B9DAE0315 Q30563774-E78B2844-0507-4330-A002-71CAAE756F45 Q30857433-6FE98CF5-0AF7-426F-B1C0-4A131FE42B7D Q33405318-317DF35A-25E4-48EA-89A2-FD0699AE4C75 Q33409364-290F45C0-FF83-40E0-A13B-88322398EC7E Q33411581-7F04D0D9-A06D-45A5-B6CE-626DBDEEFAAF Q33413496-0DAD4D8C-2CCA-40A8-8774-6862DF331D2A Q33578564-02FEC0BF-62C5-439F-A104-8DAB48B0C052 Q33923405-D09AFB0C-3E92-4098-B21A-288814FDC49E Q33938637-52E46CF6-40CE-4DA9-A5F5-98082E27A882 Q34094103-510B8193-0325-4B38-9A82-9DBC13FACDBB Q35227771-96DE6358-01D5-4801-AF3D-D90DFF293A62 Q36062762-0779FBA4-051A-452B-859E-D4F566F071AE Q36267685-4C67611B-9DFF-4CC5-AEF3-E31B0B1E3F70 Q36995686-80F07ED7-F44A-40EA-9C9E-A357ADC4F6F6 Q37108266-3C591071-7AAA-4C60-B1BE-5B1A9C654147 Q37261102-493CE910-C394-4152-BEC2-3A4EDC080EC3 Q37305943-C428B3B7-3AFA-4D00-A32B-AC4E289878FA Q37392963-15622DA3-1887-4955-A789-031673F9639C Q37527255-51CDF110-4C0F-467C-A6E8-5C84F127018F Q37579125-C7F16DE5-4750-4AE5-BF25-F0D0BC525FDD Q37773367-60F6043D-6A46-4F32-B95B-DF865C7B4920 Q37821892-89AC0390-94F4-4A37-A765-39FD4D0CEF12 Q37888549-653D51A5-EF37-45DA-A053-3E660D9A1EAA Q37894683-1F256DDD-43F7-4964-BD98-9FD6D0FEFB61 Q37960909-8210BC6B-3D3F-4613-B527-D04ADC68800E Q37965638-8CA2A0EF-6647-41FA-BE92-2BE6276332E0 Q38003195-7D4FFA19-BE7D-4055-818C-8C1F0500A86E Q38092022-46772AC2-ABB5-4F62-A258-09333879B828 Q38132039-B89C273A-8FC3-4B65-BBD8-E0C403D42FE6 Q38155201-23308D6F-1853-4A96-A30D-75C06EAB578C Q38159713-4E796254-7289-4C1A-BFB7-158A154C15B5 Q38160271-18594FA2-D453-4545-9382-8E2E1C8B8F08 Q38181169-F8854DEA-B8E4-4CC5-9F11-A1D0F362F600

P2860

Phase II study of sunitinib in patients with metastatic urothelial cancer.

http://www.wikidata.org/entity/Q43168171

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Phase II study of sunitinib in patients with metastatic urothelial cancer.

@en

Phase II study of sunitinib in patients with metastatic urothelial cancer.

@nl

type

label

Phase II study of sunitinib in patients with metastatic urothelial cancer.

@en

Phase II study of sunitinib in patients with metastatic urothelial cancer.

@nl

prefLabel

Phase II study of sunitinib in patients with metastatic urothelial cancer.

@en

Phase II study of sunitinib in patients with metastatic urothelial cancer.

@nl

P1433

Q43168171-EA3943EE-E31D-47AF-82C0-584E0808CEDF

P1476

Q43168171-24396C3C-1439-4B3A-9A08-F1A4D9FC951A

P2093

Q43168171-00EFD02F-DCFD-480B-8AB8-B9003FF4F6E5

Q43168171-0D4E5A49-3487-478F-853C-98EB2474FE2F

Q43168171-23E2072C-EAF8-4BE8-9219-802E5383124A

Q43168171-527A2CAC-DAC5-46E1-8BEF-1D0847FB1DB4

Q43168171-6AC6ABDE-E437-4CFC-9CCF-E579CA7F56C9

Q43168171-874CFF7E-1906-4907-998A-872102C32B2A

Q43168171-883BAAE1-B753-4A9C-9103-112AEB45A722

Q43168171-D0F70991-75C1-43D3-A64A-4106ED2E5276

Q43168171-F3E7B9FC-1689-451F-ADB6-D8C2AAE1AD81

P304

Q43168171-E63AC781-B45A-499A-A05A-CF355DA89099

P31

Q43168171-EE2B7659-9B41-4B1F-9A1F-B92808942E44

P356

Q43168171-F3185BE7-ED61-4153-9A71-0E93EB800AA3

P407

Q43168171-DDA276DD-3E8E-42FE-A571-91D129B3B4DD

P433

Q43168171-CAFEC48E-C570-487C-8DC4-F569D8CD9E93

P478

Q43168171-7585A804-8F85-4E66-9946-FAA451CB53A1

P50

Q43168171-DDC526C2-2422-44B8-B369-7C6712CBDDFE

P577

Q43168171-CD5E24F0-8DF6-47E0-A79C-06D96C6D2B98

P698

Q43168171-725CA38A-09A2-4D1B-918A-BBDCF4E3B63F

P356

JCO.2009.25.3922

P1433

Journal of Clinical Oncology

P1476

Phase II study of sunitinib in patients with metastatic urothelial cancer.

@en

P2093

Alisa Trout

http://www.w3.org/2001/XMLSchema#string

Anne-Marie Flaherty

http://www.w3.org/2001/XMLSchema#string

Ashley Regazzi

http://www.w3.org/2001/XMLSchema#string

Dean F Bajorin

http://www.w3.org/2001/XMLSchema#string

Jamie Riches

http://www.w3.org/2001/XMLSchema#string

Mary G Boyle

http://www.w3.org/2001/XMLSchema#string

Matthew I Milowsky

http://www.w3.org/2001/XMLSchema#string

Nicole Ishill

http://www.w3.org/2001/XMLSchema#string

Scott R Gerst

http://www.w3.org/2001/XMLSchema#string

P304

1373-1379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.25.3922

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

David J Gallagher

P577

2010-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20142593

http://www.w3.org/2001/XMLSchema#string